Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | CCNK | O75909 | 2/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399174 | 1.00 | HPGD (0.46) | HPGDMAPTKMT2AMEN1MAPK1 | |
| SCHEMBL1257914 | 0.96 | HRH4 (0.46) | HPGDMAPTKMT2AMEN1MAPK1 | |
| SCHEMBL6372844 | 0.96 | HRH4 (0.46) | HPGDMAPTKMT2AMEN1MAPK1 | |
| SCHEMBL12916739 | 0.91 | KDM4E (0.47) | MAPTSMN1; SMN2HSD17B10HCRTR1HCRTR2 | |
| SCHEMBL6372053 | 0.91 | KDM4E (0.47) | MAPTSMN1; SMN2HSD17B10HCRTR1HCRTR2 | |
| SCHEMBL1255999 | 0.91 | KDM4E (0.47) | MAPTSMN1; SMN2HSD17B10HCRTR1HCRTR2 | |
| SCHEMBL1258353 | 0.91 | HCRTR1 (0.45) | HPGDTP53HSD17B10HCRTR1HCRTR2 | |
| SCHEMBL6372182 | 0.91 | HCRTR1 (0.45) | HPGDTP53HSD17B10HCRTR1HCRTR2 | |
| SCHEMBL1258218 | 0.86 | HRH3 (0.49) | MAPTKMT2AMEN1MAPK1STAT3 | |
| SCHEMBL6373344 | 0.86 | HRH3 (0.49) | MAPTKMT2AMEN1MAPK1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364420-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364420-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364420-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8648197-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130123270-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123270-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8168788-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168788-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168788-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110237601-A1 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237601-A1 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237601-A1 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-7880002-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880002-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237601-A1 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | ACKR3, CCR5, CCR2 | HPGD 248/4885MAPT 4863/4885KMT2A 4131/4885 |
| US-20140364420-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | ACKR3, CCR5, CCR2 | HPGD 248/4885MAPT 4863/4885KMT2A 4131/4885 |
| US-20130123270-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | ACKR3, CCR5, CCR2 | HPGD 248/4885MAPT 4863/4885KMT2A 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.